Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Leuk Res. 2019 Jan 7;77:42–50. doi: 10.1016/j.leukres.2018.11.010

Table 1.

Summary of BET inhibitors in clinical trials for hematological malignancies.

Summary of BET inhibitors in Clinical Trials
BET Inhibitor Indication Clinical Status Reference
CPI-0610 Leukemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders Phase I NCT02158858 [11]
OTX 015 Acute Myeloid Leukemia; Diffuse Large B-cell Lymphoma; Acute Lymphoblastic Leukemia; Multiple Myeloma Phase I NCT01713582; NCT02698189 [13]
RO 6870810; TEN 010 AML; myelodysplastic syndrome Phase I NCT02308761
INCB-054329 Advanced malignancies Phase I/II NCT02431260
ABBV-075 Advanced malignancies Phase I NCT02391480
FT 1101 Hematological malignancies Phase I NCT0254387 [15]
GSK525762; I-BET-762 Relapsed, refractory hematological malignancies, solid tumors Phase I/II NCT01943851 [12]
PLX-51107 AML, myelodysplasia, solid tumors Phase I NCT02683395 [16]